Tubal motility inhibition

Tubal motility inhibition refers to the reduction or cessation of muscular and/or ciliary activity in the Fallopian tube, lowering transport efficiency of gametes and embryos. This outcome is primarily produced by increased progesterone levels (stimulating β-adrenergic receptors and relaxing tubal musculature), the action of certain progestins (levonorgestrel, mifepristone), and specific prostaglandins (e.g. PGE1/PGE2)[1][3][6]. Inhibition occurs physiologically after ovulation to facilitate transfer of the fertilized ovum but may be pathologically excessive, increasing risk for tubal ectopic pregnancy and infertility[5]. Numerous drugs modulate tubal motility via these mechanisms, and direct molecular targets include steroid hormone receptors, prostaglandin receptors, adrenergic receptors, and CB1 cannabinoid receptors[2][3][5][6].

Other names

inhibition of fallopian tube motilityreduced tubal contractility

Modulation of progesterone receptors (relaxation/inhibition), prostaglandin receptors (PGF2α stimulates contraction, PGE1/2 inhibit), adrenergic receptors (β-adrenergic activation inhibits motility), CB1 cannabinoid receptor, Direct smooth muscle relaxation/inhibition, Ciliary beat reduction